UBS analyst David Dai reiterated a Buy rating and $33.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE